Trusted by 10,000+ Businesses

Statutory Audit for Healthcare Companies in India 2026

Reviewed by CA and CS Team, Patron Accounting LLP ICAI & ICSI Registered| 15+ Years Experience| Last Updated: Verify Credentials →

Six Sector-Specific Risk Areas: Clinical trial revenue and grants, pharma inventory expiry (SA 501), TPA receivables ageing, Section 35 R and D, drug licence/DPCO, and patient receivables ECL - all under one CA partner.

SA 501 Plant + Pharmacy Count: Partner-led year-end physical inventory at manufacturing plant, warehouse, and retail pharmacy - FEFO adherence, cold-chain logs, Schedule M reconciliation.

Section 35(2AB) Form 3CLA: Cost-ledger R and D segregation by trial phase and DSIR Form 3CL bucket - single-partner Form 3CLA sign-off, not a separate return months later.

Fees from Rs 70,000: Sub-sector and complexity tiered - nursing homes and small pharma units from Rs 70,000; scales by inventory complexity, R and D claim, and TPA volume.

Trust: 10,000+ Businesses Served | 4.9 Google Rating | 50,000+ Documents Filed | 15+ Years

Call +91 945 945 6700 Email Us WhatsApp Us

15+ YearsIndustry Experience

CA & CSCertified Experts

4.9

Based on 500+ reviews

Get Free Consultation

Talk to a CA/CS expert today

Full Name

Phone Number

City

Service Needed

Our team will get back to you shortly. No spam.

Real Stories from Real People

Hear how teams across industries use Patron to save time, cut costs, & stay in control.

“

The statutory audit was clean and completed well before deadline. No last-minute rush.

Trading Firm, Mumbai

★★★★★

2 months ago

“

Our GST filing is always on time since we moved to Patron. The CA team knows their stuff cold.

CFO

Manufacturing, Maharashtra

★★★★★

3 months ago

“

SA 501 partner attendance at our pharma plant and the integrated Form 3CLA saved us a separate DSIR consultant. One engagement, one team.

Finance Head

Pharma Manufacturer, Pune

★★★★★

1 month ago

“

The TPA sidecar reconciliation finally gave our board a defensible ECL provision number. Clean Ind AS 109 workpaper.

CFO

Hospital Chain, NCR

★★★★★

4 months ago

Join 10,000+ Satisfied Businesses

Hospitals, pharma manufacturers, nursing homes, diagnostic chains, and CROs trust Patron's single-partner healthcare audit, SA 501 plant attendance, TPA sidecar reconciliation, and integrated Section 35(2AB) Form 3CLA.

Talk to an Expert

10,000+Businesses ServedGST compliance and litigation support across India.

15+Years ExperienceDeep expertise in IP registration, GST & business compliance.

50,000+Documents FiledReturns, appeals, and filings handled accurately.

4.9★Client RatingTrusted by entrepreneurs, startups, and growing businesses.

ISO CertifiedProfessional standards and documented processes.

SSL SecureYour financial and business data is fully protected.

Overview What Is It Who Needs It Patron Services 6-Step Process Documents Challenges Fees Timeline Why Patron DIY vs Big-Four FAQs

Statutory Audit for Healthcare Companies - Overview

📌 TL;DR - Statutory Audit for Healthcare Services at a Glance

Statutory audit for healthcare companies in India is the annual independent examination of financial statements under Section 143 of the Companies Act, 2013, with six sector-specific risk areas: clinical trial revenue and grant accounting (Ind AS 115 + Ind AS 20), pharmaceutical inventory expiry tracking under SA 501 and Schedule M, hospital reimbursement claims and TPA receivables ageing, R and D expense disclosure under Section 35, drug licence and DPCO compliance verification, and patient receivables expected credit loss provisioning.

Healthcare audits sit at the most cross-regulated intersection of any industry in India - the Companies Act for statutory audit, the Drugs and Cosmetics Act for inventory and licence compliance, the Drugs Price Control Order 2013 for essential-drug pricing, IRDAI regulations for TPA settlement timelines, Income Tax Section 35 for R and D claims and DSIR Form 3CL annual returns, and IRDAI / Section 194J for corporate health-checkup TDS.

A pharma manufacturer in Hyderabad, a 200-bed hospital in Mumbai, a nursing home in Pune, a diagnostic chain across NCR, and a clinical research organisation (CRO) in Bengaluru all sit in the same vertical but face six different risk-area emphasis levels. Patron handles all six under one CA partner and one engagement letter. Sector references are verified against the CDSCO, NPPA, and DSIR.

Parameter	Detail
Governing Act (Statutory)	Companies Act, 2013 - Sections 139 to 148
Applicable To	Every Indian healthcare company - Pvt Ltd / Public / OPC / Section 8; LLPs above Rs 40 lakh turnover
Inventory Standard	AS 2 / Ind AS 2 - lower of cost or NRV; SA 501 physical verification; FEFO for pharma; CARO clause 3(ii) 10% threshold
Revenue Standards	Ind AS 115 for hospital and clinical-trial revenue; AS 9 for non-Ind AS entities; insurance receivable on accrual
R and D (Section 35)	100% deduction under Sec 35(1)(i); Sec 35(2AB) weighted deduction reduced from 200% to 100% from 1 April 2020; clinical drug trial included by Explanation
Cost Starting From	Rs 70,000 (Patron - small nursing home or pharma unit, turnover under Rs 5 crore)
Sector Regulators	CDSCO (drug licence), NPPA (DPCO ceiling prices), IRDAI (insurance / TPA), DSIR (R and D approval), DGHS, Drug Inspectors

Content is reviewed quarterly for accuracy.

What Is Statutory Audit for Healthcare Companies

Statutory audit for healthcare companies is the legally mandated annual examination of financial statements under Section 143 of the Companies Act, 2013, covering six sector-specific risk areas: clinical-trial revenue and grant accounting, pharmaceutical inventory expiry, hospital TPA receivables, Section 35 R and D claims, drug-licence and DPCO compliance, and patient receivables.

It is conducted by an independent practicing Chartered Accountant holding a valid Certificate of Practice from ICAI. The audit applies to every Indian healthcare company regardless of size or surplus - a single-doctor nursing home in stub-period year one and a 500-bed multi-speciality hospital chain crossing Rs 500 crore turnover are equally bound. The auditor's opinion under SA 700 is filed with the Registrar of Companies in Form AOC-4 within 30 days of the AGM, and Form ADT-1 intimates auditor appointment within 15 days of the board resolution.

The depth of testing in healthcare audits is dominated by inventory and receivables. Pharmaceutical inventory is split across raw APIs, excipients, work-in-progress (granulation / blending / compression batches), finished goods on FEFO (First Expired First Out), expired and near-expiry stock, and Schedule H / H1 / X controlled substances - each with its own SA 501 procedure. Hospital revenue routes 40 to 60 percent through TPAs and insurers under the IRDAI 30-day cashless settlement and 45 to 90-day reimbursement windows, generating a receivable that needs ageing analysis and Ind AS 109 expected credit loss (ECL) provisioning.

Key Terms for Statutory Audit for Healthcare:

FEFO - First Expired, First Out - inventory dispatch principle in pharma where stock closest to expiry is consumed first. The auditor tests FEFO adherence as part of SA 501 inventory observation.

Schedule M - Schedule to the Drugs and Cosmetics Rules, 1945 prescribing Good Manufacturing Practices (GMP) for premises, plant, equipment, sanitation and documentation. Non-compliance can lead to drug-licence suspension under Section 27 of the Drugs and Cosmetics Act, 1940.

DPCO 2013 / NPPA - Drugs (Prices Control) Order, 2013 - sets ceiling prices for National List of Essential Medicines (NLEM) molecules; the National Pharmaceutical Pricing Authority (NPPA) notifies revisions. The auditor cross-checks invoiced selling price against the NPPA-notified ceiling.

TPA - Third Party Administrator - IRDAI-licensed intermediary between hospitals, insurers and patients for cashless and reimbursement claims processing.

Section 35(2AB) - Income Tax Act provision allowing a deduction (100% since 1 April 2020; earlier 150% from FY 2017-18 to FY 2019-20 and 200% prior) on expenditure on in-house R and D approved by DSIR for companies in biotechnology, pharma (including clinical drug trials), chemicals and select sectors.

Form 3CL - Annual report of in-house R and D expenditure filed by the company with DSIR; the auditor's certificate (Form 3CLA) is annexed and supports the Section 35(2AB) claim in the audit.

SA 501 Healthcare

Who Needs Statutory Audit (Healthcare)

Statutory audit applies to every company incorporated under the Companies Act, 2013 - no revenue threshold and no exemption based on size. For healthcare entities the applicability stacks by sub-sector:

Healthcare Sub-sector	Examples	Audit Layers
Pharmaceutical manufacturer	API maker, formulation plant, biosimilar producer	Sec 143 + SA 501 (FEFO) + Schedule M + Sec 148 cost records (above Rs 35 cr) + Sec 35(2AB) R and D + DPCO
Hospital / multi-speciality	Tertiary-care chain, single-unit 100-300 bed hospital	Sec 143 + Ind AS 115 (hospital revenue) + TPA receivable ageing + Sec 194J TDS on corporate checkups
Nursing home / clinic	10 to 50-bed nursing home, OPD clinic	Sec 143 (mandatory for Pvt Ltd or LLP above thresholds) + AS 9 revenue + drug licence Form 20/21 verification
Diagnostic chain / pathology lab	Multi-collection-centre lab, imaging chain	Sec 143 + Ind AS 115 (sample-collection vs report-issuance cut-off) + B2B Sec 194J reconciliation
Clinical Research Organisation (CRO)	Phase I-IV trial sites, bio-analytical labs	Sec 143 + Ind AS 115 milestone revenue + Ind AS 20 grant accounting (ICMR / DBT / BIRAC) + Sec 35(2AA) sponsored research
Pharma distributor / wholesale stockist	C and F agent, super-stockist, retail pharmacy	Sec 143 + SA 501 inventory + GST e-invoicing reconciliation + drug licence Form 20B / 21B
Section 8 charitable hospital / trust	Mission hospital, charitable nursing home	Sec 143 + Section 12A and 80G compliance audit overlay + Sec 35AC / 80G certification trail

For tax audit applicability under Section 44AB, healthcare entities cross the Rs 1 crore turnover threshold (Rs 10 crore for digital receipts above 95 percent). Cost records under Section 148 apply to pharma manufacturers in the Table A regulated sector (drugs and pharmaceuticals) once turnover crosses Rs 35 crore in the preceding financial year. CARO 2020 applies to all healthcare companies except micro / small entities and Section 8 companies meeting the small-company thresholds.

Patron Services Included

Service	What We Do
Section 143 Full-Scope Statutory Audit	Companies Act 2013 audit with CARO 2020 21-clause annexure; SA 700 / 705 reporting; Ind AS or AS framework as applicable.
Pharmaceutical Inventory Audit (SA 501 + Schedule M)	Year-end physical count at plant, warehouses and retail pharmacies; batch-wise verification with manufacturing date, expiry date, storage temperature log; FEFO adherence testing; expired/slow-moving write-down under Ind AS 2 / AS 2; Schedule M Form 14 reconciliation.
Hospital Revenue and TPA Receivables Audit	Ind AS 115 contract testing for inpatient, outpatient, pharmacy and diagnostic revenue; TPA receivable ageing across cashless and reimbursement buckets; Ind AS 109 ECL provisioning for disputed/aged claims; Section 194J TDS reconciliation for corporate health-checkup receipts.
Clinical Trial Revenue and Grant Accounting	Milestone-based revenue under Ind AS 115 for CRO Phase I-IV trials; grant accounting under Ind AS 20 / AS 12 for ICMR, DBT, BIRAC and CSIR grants; deferred income vs revenue treatment; refund-obligation analysis where a trial fails a milestone.
Section 35 R and D Disclosure and DSIR Form 3CL Audit	Verification of DSIR approval (Form 3CM) and annual return (Form 3CL); Form 3CLA certificate on revenue and capital R and D expenditure; segregation of clinical-trial spend, regulatory approval costs and patent filing fees under the Section 35(2AB) Explanation; weighted-deduction quantification.
DPCO and Drug Licence Compliance Audit	Verification of valid CDSCO manufacturing licence (Forms 25 / 28) or wholesale/retail licence (Forms 20B / 21B / 20 / 21); NPPA ceiling price compliance for NLEM molecules under DPCO 2013; markup-check on inter-state stock transfers; Section 27 D and C Act penalty exposure flagged.

Our Process

Healthcare Statutory Audit Process - 6 Steps

From healthcare risk profiling and SA 501 plant/pharmacy count through TPA ECL provisioning and Section 35 R and D workpapers to UDIN sign-off and AOC-4 filing.

Step 1

Engagement and Healthcare Risk Profiling

SA 210 engagement letter, Section 141 independence certificate, and a sub-sector risk profile - cataloguing pharma manufacturing licences and Schedule M status, hospital TPA empanelments and Section 135 CSR, or CRO live trials by phase and grant contracts.

SA 210 + Sec 141 Sub-sector profile

Profiled01

Step 2

SA 501 Physical Inventory Count at Pharmacy and Warehouse

Year-end count attended by the audit partner - raw APIs, excipients, WIP stages, finished goods on FEFO, expired/near-expiry stock, Schedule H/H1/X controlled substances; cold-chain logs tested; write-downs reviewed against Ind AS 2 / AS 2 and GST Section 17(5).

FEFO + cold chain Schedule M Form 14

Counted02

Step 3

TPA Receivables Ageing and ECL Provisioning

Test the TPA receivable subsidiary ledger by ageing bucket and TPA-wise; sidecar reconciliation of claim numbers to bank credits beyond the IRDAI 30-day window; Ind AS 109 ECL using historical recovery rates; Section 194J TDS reconciled to Form 26AS.

Ageing buckets Ind AS 109 ECL

Aged03

Step 4

Clinical Trial Revenue and Grant Accounting

Review each clinical trial agreement against Ind AS 115 - performance obligations, transaction-price allocation, over-time vs point-in-time recognition; grants from ICMR/DBT/BIRAC/CSIR tested under Ind AS 20 / AS 12 for deferred-income and refund obligations.

Ind AS 115 Ind AS 20 grants

Recognised04

Step 5

Section 35 R and D and DSIR Form 3CL Workpapers

Verify DSIR Form 3CM approval validity, physical R and D segregation, eligible revenue and capital expenditure segregation, Form 3CLA reconciliation to Form 3CL, and the Section 35(2AB) deduction computed at 100% (FY 2020-21 onwards).

Form 3CM + 3CLA Cost segregation

Certified05

Step 6

Sign-Off, UDIN and AOC-4 Filing

Audit partner signs under UDIN generated on the ICAI portal; report annexed to Form AOC-4 and filed with the RoC within 30 days of the AGM; MGT-7 within 60 days; Form 3CL with DSIR; Form CRA-4 for pharma above Rs 35 crore.

UDIN sign-off AOC-4 + 3CL

Filed06

Documents Checklist for Healthcare Audit

What you need to share so Patron can plan and execute the healthcare statutory audit efficiently:

Trial balance and general ledger - year-end TB plus full ledger scroll
Pharma inventory records - batch-wise stock register with manufacturing date, expiry date, BMR / BPR reference, FEFO dispatch trail
Schedule M production records - Form 14 batch manufacturing records; cleaning records; deviation register
Drug licences - manufacturing Forms 25 / 28; wholesale Forms 20B / 21B; retail Forms 20 / 21; current validity copies
Cold-chain temperature logs - for vaccines, biologics, insulin, oncology biosimilars (daily reefer truck and storage logs)
TPA receivable ledger - TPA-wise outstanding with cashless / reimbursement split; ageing buckets; sidecar settlement files
IRDAI TPA empanelment letters - all empanelled TPAs and direct insurers; rate cards; package agreements
Patient receivable ledger - self-pay vs insurance vs corporate; ageing; write-off authorisations
Clinical trial agreements - sponsor MSA, protocol, milestone schedule, payment trigger events
Grant letters and utilisation certificates - ICMR / DBT / BIRAC / CSIR grant letters; periodic UCs; refund clauses
DSIR approval and Form 3CL - Form 3CK application, Form 3CM approval order, current-year Form 3CL with Form 3CLA
NPPA ceiling price notifications - for NLEM molecules in the portfolio; monthly compliance check log
GST returns and ITC reversal working - GSTR-1, GSTR-3B, GSTR-9, GSTR-9C; Section 17(5) ITC reversal on destroyed expired stock; ITC-04 for job-work
Section 194J TDS working - corporate health-checkup receipts with 10% TDS reconciled to Form 26AS

Common Healthcare Audit Challenges and Solutions

Challenge	Impact	How Patron Accounting Solves It
Expired Stock Write-Down and GST ITC Reversal Trail	Pharma destroys expired stock at year-end with witnessed destruction certificate, pollution-board approval, and Drug Inspector format - three trails must reconcile.	Reconcile in a single working paper - (a) Ind AS 2 / AS 2 write-down through COGS; (b) Section 17(5) CGST ITC reversal on destroyed-stock inputs; (c) destruction documented in the Drug Inspector format. A gap on any leg creates CARO clause 3(vii) exposure.
TPA Receivable Ageing and Disputed Claim Provisioning	Hospital TPA receivables routinely sit at 60 to 120 days because partial disallowances and queries restart the clock past the IRDAI 30-day window.	Test TPA-wise ageing, the sidecar reconciliation between bank credits and claim-level approvals, and the historical recovery rate by TPA; quantify the Ind AS 109 ECL provision for each bucket separately - cashless authorised but unsettled, reimbursement under-review, disputed, and disallowed.
Section 35(2AB) Clinical Trial Cost Segregation	Pharma running both manufacturing and in-house R and D must segregate eligible clinical-trial expenditure from manufacturing cost.	The Explanation to Section 35(2AB) includes clinical drug trial, regulatory approval, and patent-application costs. Patron segregates each cost ledger by trial phase and DSIR Form 3CL bucket - avoiding the common errors of classifying CMO manufacturing trial batches or Phase IV surveillance as R and D.
NLEM / DPCO Ceiling Price Overshoot	If invoiced MRP crosses the NPPA ceiling, the overcharged amount is recoverable with 15 percent interest under DPCO 2013 paragraph 19.	Flag any product-month where invoiced MRP exceeded the NPPA ceiling and any provision for recoverable overcharge in the books - this sits in CARO clause 3(vii) statutory dues disclosures.

Patron Fees for Healthcare Statutory Audit

Fee Component	Amount
Nursing home / single OPD clinic (turnover under Rs 5 cr)	Rs 70,000 to Rs 1,40,000 (Exl GST) - 3 to 4 weeks
Pharma retail / wholesale (turnover under Rs 10 cr)	Rs 85,000 to Rs 1,75,000 (Exl GST) - 4 weeks
Single-unit hospital 50 to 200 beds (turnover Rs 10 to 50 cr)	Rs 2,00,000 to Rs 4,50,000 (Exl GST) - 5 to 6 weeks
Pharma manufacturer with Schedule M GMP (turnover Rs 10 to 50 cr)	Rs 2,25,000 to Rs 5,00,000 (Exl GST) - 5 to 6 weeks
Pharma above Rs 35 cr - cost records overlay (Sec 148)	Add Rs 75,000 to Rs 1,50,000 (Exl GST) - same window
Section 35(2AB) R and D claim - Form 3CLA certification	Add Rs 60,000 to Rs 2,25,000 (Exl GST) - same window
Diagnostic chain / CRO (multi-location, milestone revenue)	Rs 3,00,000 to Rs 7,50,000 (Exl GST) - 6 to 7 weeks
Multi-speciality hospital chain / listed pharma	From Rs 8,00,000 (Exl GST) - 7 to 9 weeks
Patron Accounting Professional Fees	Starting from Rs 70,000 (Exl GST and Govt. Charges)

All fees and charges listed are indicative only and do not constitute a binding offer. Final amounts may vary depending on the volume of work and the complexity involved.

Professional service charges for drafting, filing, and representation are separate from the statutory fees. The exact fee depends on the complexity of the case, disputed amount, and number of hearings required. Contact us for a detailed quote.

Get a free Statutory Audit for Healthcare consultation - Call +91 945 945 6700 or WhatsApp us. No-obligation assessment.

Healthcare Statutory Audit Timeline

Stage	Estimated Timeline
Engagement and planning (Week 1)	SA 210 engagement letter; Section 141 independence; drug licence and DSIR Form 3CM verification
Pre-year-end interim audit (Weeks 2 to 3)	Q4 substantive testing; TPA ageing preview; clinical trial milestone walkthrough
SA 501 physical inventory count (31 March + 1 to 2 days)	Plant + pharmacy + central drug store + retail outlets; cold-chain log testing
TPA receivable circularisation (Weeks 4 to 6)	Direct confirmations from top TPAs; ageing analysis; ECL provisioning
Section 35(2AB) R and D segregation (Weeks 4 to 5, parallel)	Cost ledger segregation; Form 3CLA preparation
Draft report and management response (Weeks 6 to 7)	SA 700 / 705 review; KAM discussion for listed entities
UDIN, sign-off and AOC-4 filing (within 30 days of AGM)	Patron files AOC-4 with audit report annexed
Form 3CL filing with DSIR (by 31 October)	Annexed with Form 3CLA auditor certificate
Form CRA-4 cost audit filing (pharma above Rs 35 cr)	Within 30 days of receipt of cost audit report; coordinated with cost auditor

Filing deadlines: AOC-4 with audit report within 30 days of the AGM; MGT-7 within 60 days; Form 3CL for the DSIR annual R and D return typically by 31 October annexing Form 3CLA; Form CRA-4 cost audit within 30 days of receipt for pharma above Rs 35 crore turnover. DPCO 2013 paragraph 19 overcharge carries 15 percent interest until repaid - a growing statutory-dues exposure if unidentified at audit. Delay attracts Rs 100 per day in MCA additional fees plus Section 147 penalty of Rs 25,000 to Rs 5,00,000 on the company.

Key Benefits

Benefits of Patron-Led Healthcare Audit

Single CA Partner, Six Risk Areas

One partner across pharma inventory FEFO/expiry, TPA receivables ageing, clinical trial revenue and grants, Section 35 R and D, DPCO and drug licence, and patient receivables ECL - eliminating workpaper duplication across separate firms.

Single Engagement Letter

Covers Section 143 statutory audit, SA 501 inventory at plant and pharmacy, TPA receivable testing, Form 3CLA certification, and DPCO compliance flagging - one scope, one team.

SA 501 Partner Attendance

Audit partner attends the year-end count - the NFRA enforcement precedent that penalised CAs for skipping plant attendance applies equally to pharma manufacturing and hospital pharmacy.

TPA Sidecar Reconciliation

Claim-level matching to bank credits, not aggregate-only acceptance - the only defensible basis for the Ind AS 109 ECL provision on aged and disputed TPA receivables.

Integrated Section 35(2AB) Segregation

Cost segregation prepared from the cost ledger directly, not from a separate R and D return prepared months after the audit - with NPPA ceiling-price overshoot flagged before sign-off.

Healthcare-Aware KAM Wording

Key Audit Matters drafted for listed pharma and hospital chains under SA 701 - revenue recognition, expired/slow-moving inventory provisioning, and ECL on TPA and patient receivables.

Social Proof

10,000+ Businesses | 4.9 Google Rating | 50,000+ Documents Filed | 15+ Years

"The statutory audit was clean and completed well before deadline. No last-minute rush."
- MD, Trading Firm, Mumbai

"Our GST filing is always on time since we moved to Patron. The CA team knows their stuff cold."
- CFO, Manufacturing, Maharashtra

Trusted by Hyundai, Asian Paints, Bridgestone, and healthcare clients across Mumbai's diagnostic chains, Pune's pharma cluster, and Delhi-NCR's hospital networks.

4-Office Signal: With offices in Pune, Mumbai, Delhi and Gurugram, Patron serves hospitals, pharma manufacturers and nursing homes across Hyderabad's Genome Valley, Mumbai's diagnostics ecosystem, Pune's Hinjewadi biotech cluster, and Gurugram's hospital chain corridor.

Comparison - DIY / Big-Four / Patron-Led Healthcare Audit

Factor	DIY / In-House	Big-Four	Patron-Led
Independence under Section 141	Disqualified	Qualified	Qualified
SA 501 inventory attendance (multi-site)	Not signable	Centralised - slower turnaround	Partner-led; multi-site sub-teams
TPA receivable sidecar reconciliation	Self-reconciliation rejected	Heavy procedure	Calibrated to your TPA mix
Section 35(2AB) Form 3CLA	Cannot sign	Separate tax partner	Single-partner sign-off; integrated
DPCO / drug-licence flagging	Self-flagged	Typically not bundled	Bundled as part of compliance memo
Cost (mid-size hospital 100 to 200 beds)	Apparent zero - unsignable	Rs 10 to 25 lakh	Rs 2 to 4.5 lakh
Bottom line: Statutory audit cannot be performed in-house - Section 141 disqualifies all officers and employees. For hospital chains and listed pharma, Big-Four scale may be appropriate; for nursing homes, single-unit hospitals, pharma manufacturers up to Rs 100 crore turnover and most CROs, a senior partner-led mid-tier firm typically delivers comparable assurance at one-fifth the Big-Four fee, with faster turnaround.

Related Services

Pair the healthcare statutory audit with related Patron services:

Statutory Audit in India - the parent India service page.
Tax Audit (Section 44AB) - bundled for healthcare entities above Rs 1 cr (Rs 10 cr digital) turnover.
Internal Audit (Section 138) - mandatory above Rs 200 cr turnover; recommended for multi-unit hospitals.
Stock Audit - lender-mandated quarterly stock audit; complements CARO 3(ii) for pharma.
GST Audit - GSTR-9C reconciliation above Rs 5 cr turnover; Section 17(5) destroyed-stock ITC reversal.
Private Limited Company Compliance - ROC annual filings.
Healthcare Sector Accounting Services - ongoing books, TPA reconciliation, NPPA pricing tracker.
Payroll for Healthcare Industry - doctor consultancy fee + Section 194J TDS.
Appointment of Auditor - first auditor and AGM appointment with ADT-1 filing.
Change of Auditor - Section 140 resignation and replacement.

Legal and Compliance Framework

Companies Act, 2013 (Sections 139 to 148) - Section 139 (first auditor within 30 days; AGM appointment for 5 years individual / 10 years firm); Section 143 (powers and duties; SA 700 / 705 reporting; CARO 2020 annexure); Section 147 (penalty - company and auditor Rs 25,000 to Rs 5,00,000, Rs 1 lakh to Rs 25 lakh fraudulent; officer in default Rs 10,000 to Rs 1,00,000); Section 148 (cost records mandatory for pharma manufacturers above Rs 35 crore turnover - Table A regulated sector).

Income Tax Act 1961 - Section 35(1)(i) 100% revenue deduction for in-house scientific research; Section 35(1)(ii) 100% for approved research association/university/IIT; Section 35(2AA) 100% for payments to National Laboratory/IIT for approved programmes (Form 3CG / 3CH); Section 35(2AB) weighted deduction - 200% pre-FY 2017-18, 150% FY 2017-18 to FY 2019-20, 100% from FY 2020-21 (Explanation includes clinical drug trials, regulatory approval costs, patent filing fees); Section 194J 10% TDS on professional fees; Rule 6 / 6(4) (Form 3CK / 3CM / 3CL with 3CLA).

Drugs and Cosmetics Act, 1940 - Section 18 (manufacture/sale/distribution offences); Section 27 (penalties up to imprisonment); Schedule M (GMP). Drug licence forms - Forms 25 / 28 (manufacturing allopathic); 20B / 21B (wholesale); 20 / 21 (retail). Drugs (Prices Control) Order, 2013 - NPPA ceiling prices for NLEM molecules; paragraph 19 recoverable overcharge plus 15 percent interest.

IRDAI Regulations - Health Insurance Regulations 2016 - 1-hour cashless preauthorisation; 30-day cashless settlement; 30 to 45-day reimbursement processing. GST Section 17(5) - ITC reversal on destroyed/expired goods.

Accounting Standards - Ind AS 2 / AS 2 (Inventories - lower of cost or NRV); Ind AS 20 / AS 12 (Government grants); Ind AS 109 (ECL); Ind AS 115 / AS 9 (Revenue Recognition). Standards on Auditing (ICAI) - SA 200, SA 500 / 501 / 530, SA 540 (ECL and slow-moving inventory estimates), SA 550, SA 570, SA 700 / 701 / 705 / 706. Sector verification: CDSCO, NPPA, DSIR.

CARO 2020 - Clauses 3(i) PP and E and title deeds; 3(ii) inventory + WC above Rs 5 crore; 3(vi) cost records (pharma above Rs 35 cr); 3(vii) statutory dues; 3(xv) related-party; 3(xx) CSR. Forms - ADT-1, AOC-4, MGT-7, 3CD, 3CL, 3CLA, 3CK, CRA-1 to CRA-4, Form 10-IC.

Is statutory audit mandatory for hospitals and nursing homes in India?

Yes. Section 139 of the Companies Act, 2013 makes statutory audit mandatory for every Indian company - private limited, public limited, OPC, Section 8 (which covers most charitable hospitals and trust-run nursing homes) - irrespective of turnover or surplus. A 10-bed nursing home in its first year and a 500-bed multi-speciality chain are equally bound. The first auditor must be appointed by the Board within 30 days of incorporation, and Form ADT-1 must be filed with the Registrar of Companies within 15 days of appointment.

How is pharmaceutical inventory expiry audited?

Under SA 501 the statutory auditor must attend the year-end physical inventory count where inventory is material. For pharma, this includes test counts of raw APIs, excipients, WIP, finished goods and expired stock; verification of the FEFO (First Expired First Out) dispatch trail through bin-card sampling; cold-chain temperature log inspection; Schedule M Form 14 batch manufacturing record check; and write-down review of expired and near-expiry stock under Ind AS 2 / AS 2 (lower of cost or NRV). Expired stock destruction must be witnessed and documented in the Drug Inspector's prescribed format, with GST ITC reversal under Section 17(5) of the CGST Act.

What is FEFO and why does it matter in pharma audits?

FEFO is First Expired First Out - the inventory dispatch principle under which stock closest to its expiry date is consumed first. It is the operational rule that prevents avoidable write-downs of expired drugs. The statutory auditor tests FEFO adherence as part of SA 501 procedures by sampling batch numbers across opening and closing inventory and tracing dispatch dates to ensure that older-expiry batches actually left first. Failure of FEFO surfaces in higher expired-stock write-downs and shrinks gross margin - a Key Audit Matter for pharma auditors.

How are TPA receivables aged in hospital audits?

The auditor ages the TPA receivable subsidiary ledger TPA-wise in standard buckets: 0 to 30 days, 31 to 60 days, 61 to 90 days, 91 to 180 days, and over 180 days. Under IRDAI Health Insurance Regulations, cashless claims must be settled within 30 days of discharge and reimbursement claims within 30 days of complete documentation. Beyond these windows the auditor reviews the sidecar settlement file to match each claim number to the bank credit, identifies disputed and partially disallowed claims, and applies an expected credit loss provision under Ind AS 109 based on the historical recovery rate by TPA.

Is clinical trial revenue recognised at milestone or over time?

Under Ind AS 115, the treatment depends on the contractual performance obligations. If the clinical trial deliverables transfer to the sponsor over the trial duration (such as ongoing data monitoring or report submissions), revenue is recognised over time using an input or output method. If the deliverables transfer at distinct milestones (such as 'protocol design complete', 'patient recruitment milestone', 'final clinical study report submitted'), revenue is recognised at each milestone subject to the variable consideration constraint under paragraph 56. The audit reviews the contract and the standalone selling price allocation across performance obligations.

What R and D deduction can pharma companies claim under Section 35?

Under Section 35(2AB) of the Income Tax Act, 1961, companies engaged in biotechnology or manufacture of articles not listed in the Eleventh Schedule, with an in-house R and D facility approved by DSIR, are entitled to a deduction on revenue and capital R and D expenditure (excluding land and building). The deduction rate is 100 percent from FY 2020-21 onwards, having been 150 percent from FY 2017-18 to FY 2019-20 and 200 percent before that. The Explanation specifically includes expenditure on clinical drug trials, obtaining regulatory approvals, and patent applications - critical for pharma. Section 35(1)(i) separately allows 100 percent deduction for in-house scientific research not approved under (2AB).

What is DSIR Form 3CL?

Form 3CL is the annual report of in-house R and D expenditure that companies claiming Section 35(2AB) deduction must file with the Department of Scientific and Industrial Research (DSIR) under Rule 6 of the Income Tax Rules, 1962. The form details revenue and capital R and D expenditure for the year, segregated by approved cost categories. The statutory auditor or tax auditor signs Form 3CLA (the auditor's certificate annexed to 3CL) certifying that the expenditure reflected has been audited and is fairly stated. DSIR review of Form 3CL is the basis on which the actual quantum of deduction is allowed by the Assessing Officer.

How are grants under Section 35(2AA) accounted for in audited financials?

Government grants for sponsored scientific research from ICMR, DBT, BIRAC, CSIR or other approved bodies are accounted for under Ind AS 20 (Accounting for Government Grants) or AS 12 for non-Ind AS entities. The two permitted approaches are the income approach (grant recognised in P and L systematically over the periods in which the related costs are recognised - deferred income on the balance sheet) or the capital approach (grant deducted from the carrying amount of the related asset). Refund obligations where milestones are not met are accrued. The Section 35(2AA) deduction for the payer is 100 percent post Finance Act 2020 (earlier 150 percent).

Quick Answers

Hospital audit - Companies Act Section 143 annual examination by a practicing CA - revenue under Ind AS 115, TPA receivables ageing, SA 501 pharmacy inventory.
Pharma stock expiry - SA 501 physical count, FEFO dispatch trail, batch-wise verification, expired stock write-down, GST Section 17(5) ITC reversal.
Section 35 R and D deduction - Sec 35(2AB) is 100% from FY 2020-21 (earlier 150% / 200%); pharma clinical trial, regulatory approval, patent filing eligible per the Explanation.
DSIR Form 3CL - Annual R and D expenditure return; auditor signs Form 3CLA; DSIR review precedes the Sec 35(2AB) deduction allowance.
TPA settlement - Cashless 30 days from discharge per IRDAI; reimbursement 30 to 45 days; disputed claims often 90 to 180 days.
DPCO compliance - NPPA ceiling prices for NLEM molecules; crossing MRP triggers paragraph 19 recoverable overcharge plus 15% interest.

Urgency Recap

AOC-4 with the audit report must be filed within 30 days of the AGM and MGT-7 within 60 days. Form 3CL for the DSIR annual R and D return is typically due by 31 October following the financial year, annexing the auditor's Form 3CLA. Pharma manufacturers above Rs 35 crore turnover must file Form CRA-4 cost audit report within 30 days of receipt.

DPCO 2013 paragraph 19 overcharge recoverable carries 15 percent interest until repaid, creating a growing statutory-dues exposure quarter-on-quarter if unidentified at audit.

Delay attracts Rs 100 per day in MCA additional fees plus a Section 147 penalty of Rs 25,000 to Rs 5,00,000 on the company. Engage Patron early in the audit cycle.

Engage Patron for Your Healthcare Statutory Audit

Statutory audit for healthcare companies operates at the densest cross-regulatory intersection of any Indian industry - Companies Act statutory audit, Drugs and Cosmetics Act licensing, DPCO 2013 essential-drug pricing, IRDAI TPA settlement timelines, Section 35 R and D claims with DSIR Form 3CL annual returns, and IRDAI / Section 194J corporate health-checkup TDS. An audit that mishandles any one of these surfaces in DSIR scrutiny, NPPA notices, or Drug Inspector inspections.

Patron Accounting handles the full scope under a single CA partner with healthcare-aware risk assessment, SA 501 plant and pharmacy inventory attendance, TPA receivable sidecar reconciliation, Ind AS 115 hospital and clinical-trial revenue testing, Section 35(2AB) cost segregation with Form 3CLA, and DPCO ceiling-price compliance flagging.

Our 15+ years of practice, peer-reviewed ICAI workpapers, and four-office network across Pune, Mumbai, Delhi and Gurugram bring depth from single-unit nursing homes to multi-state hospital chains and listed pharma manufacturers. Call +91 945 945 6700 for a sub-sector-tiered fee quote.

📞 Call +91 945 945 6700 💬 WhatsApp Us ✉️ Email Us

Book a Free Consultation - No Obligation.

Patron Across India

Four offices serving hospitals, pharma manufacturers, and nursing homes across India’s major healthcare clusters.

Patron Offices

Serving Genome Valley, Mumbai diagnostics, Hinjewadi biotech, and the Gurugram hospital corridor.

Pune (HQ)

Hinjewadi Biotech

Mumbai

Diagnostics Hub

Delhi

NCR Hospital Networks

Gurugram

Hospital Chain Corridor

Audit and Healthcare Services

Pair the healthcare statutory audit with these Patron services

Healthcare Accounting

Peer Service

Healthcare Payroll

Sec 194J TDS

Content Created: 13 May 2026 | Last Updated: 13 May 2026 | Next Review: 13 August 2026 | Reviewed By: CA & CS Team, Patron Accounting LLP

This page is reviewed quarterly (Freshness Tier 1) and immediately on changes to Section 35 R and D rates, DSIR Form 3CL process, DPCO 2013 / NPPA ceiling notifications, IRDAI TPA settlement timelines, Schedule M GMP norms, or applicable Ind AS / SA standards. Verified against CDSCO, NPPA, and DSIR sources.